272 related articles for article (PubMed ID: 34821394)
1. Long-chain fatty acid oxidation and respiratory complex I deficiencies distinguish Barth Syndrome from idiopathic pediatric cardiomyopathy.
Chatfield KC; Sparagna GC; Specht KS; Whitcomb LA; Omar AK; Miyamoto SD; Wolfe LM; Chicco AJ
J Inherit Metab Dis; 2022 Jan; 45(1):111-124. PubMed ID: 34821394
[TBL] [Abstract][Full Text] [Related]
2. Barth syndrome-related cardiomyopathy is associated with a reduction in myocardial glucose oxidation.
Greenwell AA; Gopal K; Altamimi TR; Saed CT; Wang F; Tabatabaei Dakhili SA; Ho KL; Zhang L; Eaton F; Kruger J; Al Batran R; Lopaschuk GD; Oudit GY; Ussher JR
Am J Physiol Heart Circ Physiol; 2021 Jun; 320(6):H2255-H2269. PubMed ID: 33929899
[TBL] [Abstract][Full Text] [Related]
3. Tafazzin deficiency impairs CoA-dependent oxidative metabolism in cardiac mitochondria.
Le CH; Benage LG; Specht KS; Li Puma LC; Mulligan CM; Heuberger AL; Prenni JE; Claypool SM; Chatfield KC; Sparagna GC; Chicco AJ
J Biol Chem; 2020 Aug; 295(35):12485-12497. PubMed ID: 32665401
[TBL] [Abstract][Full Text] [Related]
4. Barth Syndrome: Connecting Cardiolipin to Cardiomyopathy.
Ikon N; Ryan RO
Lipids; 2017 Feb; 52(2):99-108. PubMed ID: 28070695
[TBL] [Abstract][Full Text] [Related]
5. Cardiolipin Remodeling Defects Impair Mitochondrial Architecture and Function in a Murine Model of Barth Syndrome Cardiomyopathy.
Zhu S; Chen Z; Zhu M; Shen Y; Leon LJ; Chi L; Spinozzi S; Tan C; Gu Y; Nguyen A; Zhou Y; Feng W; Vaz FM; Wang X; Gustafsson AB; Evans SM; Kunfu O; Fang X
Circ Heart Fail; 2021 Jun; 14(6):e008289. PubMed ID: 34129362
[TBL] [Abstract][Full Text] [Related]
6. Cardiac metabolic pathways affected in the mouse model of barth syndrome.
Huang Y; Powers C; Madala SK; Greis KD; Haffey WD; Towbin JA; Purevjav E; Javadov S; Strauss AW; Khuchua Z
PLoS One; 2015; 10(6):e0128561. PubMed ID: 26030409
[TBL] [Abstract][Full Text] [Related]
7. Barth syndrome cardiomyopathy: targeting the mitochondria with elamipretide.
Sabbah HN
Heart Fail Rev; 2021 Mar; 26(2):237-253. PubMed ID: 33001359
[TBL] [Abstract][Full Text] [Related]
8. Expression of human monolysocardiolipin acyltransferase-1 improves mitochondrial function in Barth syndrome lymphoblasts.
Mejia EM; Zegallai H; Bouchard ED; Banerji V; Ravandi A; Hatch GM
J Biol Chem; 2018 May; 293(20):7564-7577. PubMed ID: 29563154
[TBL] [Abstract][Full Text] [Related]
9. Restoration of mitophagy ameliorates cardiomyopathy in Barth syndrome.
Zhang J; Liu X; Nie J; Shi Y
Autophagy; 2022 Sep; 18(9):2134-2149. PubMed ID: 34985382
[TBL] [Abstract][Full Text] [Related]
10. Barth Syndrome Cardiomyopathy: An Update.
Pang J; Bao Y; Mitchell-Silbaugh K; Veevers J; Fang X
Genes (Basel); 2022 Apr; 13(4):. PubMed ID: 35456462
[TBL] [Abstract][Full Text] [Related]
11. Interplay between cardiolipin and plasmalogens in Barth syndrome.
Bozelli JC; Epand RM
J Inherit Metab Dis; 2022 Jan; 45(1):99-110. PubMed ID: 34655242
[TBL] [Abstract][Full Text] [Related]
12. The lipid environment modulates cardiolipin and phospholipid constitution in wild type and tafazzin-deficient cells.
Oemer G; Koch J; Wohlfarter Y; Lackner K; Gebert REM; Geley S; Zschocke J; Keller MA
J Inherit Metab Dis; 2022 Jan; 45(1):38-50. PubMed ID: 34494285
[TBL] [Abstract][Full Text] [Related]
13. Cardiolipin remodeling in Barth syndrome and other hereditary cardiomyopathies.
Bertero E; Kutschka I; Maack C; Dudek J
Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165803. PubMed ID: 32348916
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel mitochondrial localization signals in human Tafazzin, the cause of the inherited cardiomyopathic disorder Barth syndrome.
Dinca AA; Chien WM; Chin MT
J Mol Cell Cardiol; 2018 Jan; 114():83-92. PubMed ID: 29129703
[TBL] [Abstract][Full Text] [Related]
15. Loss of Mitochondrial Ca
Bertero E; Nickel A; Kohlhaas M; Hohl M; Sequeira V; Brune C; Schwemmlein J; Abeßer M; Schuh K; Kutschka I; Carlein C; Münker K; Atighetchi S; Müller A; Kazakov A; Kappl R; von der Malsburg K; van der Laan M; Schiuma AF; Böhm M; Laufs U; Hoth M; Rehling P; Kuhn M; Dudek J; von der Malsburg A; Prates Roma L; Maack C
Circulation; 2021 Nov; 144(21):1694-1713. PubMed ID: 34648376
[TBL] [Abstract][Full Text] [Related]
16. Phospholipid abnormalities in children with Barth syndrome.
Schlame M; Kelley RI; Feigenbaum A; Towbin JA; Heerdt PM; Schieble T; Wanders RJ; DiMauro S; Blanck TJ
J Am Coll Cardiol; 2003 Dec; 42(11):1994-9. PubMed ID: 14662265
[TBL] [Abstract][Full Text] [Related]
17. Cardiolipin deficiency in Barth syndrome is not associated with increased superoxide/H
Goncalves RLS; Schlame M; Bartelt A; Brand MD; Hotamışlıgil GS
FEBS Lett; 2021 Feb; 595(3):415-432. PubMed ID: 33112430
[TBL] [Abstract][Full Text] [Related]
18. Myocardial disturbances of intermediary metabolism in Barth syndrome.
Greenwell AA; Tabatabaei Dakhili SA; Ussher JR
Front Cardiovasc Med; 2022; 9():981972. PubMed ID: 36035919
[TBL] [Abstract][Full Text] [Related]
19. Cardiolipin deficiency affects respiratory chain function and organization in an induced pluripotent stem cell model of Barth syndrome.
Dudek J; Cheng IF; Balleininger M; Vaz FM; Streckfuss-Bömeke K; Hübscher D; Vukotic M; Wanders RJ; Rehling P; Guan K
Stem Cell Res; 2013 Sep; 11(2):806-19. PubMed ID: 23792436
[TBL] [Abstract][Full Text] [Related]
20. Clinical presentation and natural history of Barth Syndrome: An overview.
Taylor C; Rao ES; Pierre G; Chronopoulou E; Hornby B; Heyman A; Vernon HJ
J Inherit Metab Dis; 2022 Jan; 45(1):7-16. PubMed ID: 34355402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
